Introduction
The Indo-MIM IPO is a ₹3,812.11 crore mainboard IPO on the BSE and NSE, priced between ₹461 and ₹485 per share. The IPO opens on July 23, 2026, and closes on July 27, 2026, with a lot size of 30 shares and a minimum retail investment of ₹14,550 at the upper price band.
Indo-MIM Limited is the world’s largest manufacturer of metal injection molding, or MIM, components. MIM is a precision manufacturing process used to make small, complex metal parts for industries such as automotive, defence, medical devices, consumer products and aerospace. The company has a 6.8% global market share, 15 manufacturing facilities across India, the US, the UK and Mexico, and more than 1,100 customers.
The IPO includes a ₹500 crore fresh issue and a ₹3,312.11 crore Offer for Sale, meaning around 87% of the issue is OFS. Out of the fresh issue proceeds, ₹400 crore will be used for debt repayment, which is positive for the balance sheet.
This guide explains the Indo-MIM IPO price, dates, GMP, business model, financials, valuation, strengths, risks and investor suitability to help readers decide whether this IPO fits their portfolio.
Indo-MIM IPO Key Details at a Glance
| Parameter | Details |
| IPO Open / Close | July 23 – July 27, 2026 |
| Anchor Investor Bidding | July 22, 2026 |
| Allotment Date | July 28, 2026 |
| Refund / Share Credit | July 29, 2026 |
| Listing (Tentative) | July 30, 2026 — BSE & NSE |
| Issue Size | ₹3,812.11 crore | 7,86,00,300 shares | Face value ₹1 |
| Fresh Issue | 1,03,09,278 shares | ₹500 crore |
| Offer for Sale | 6,82,91,022 shares | ₹3,312.11 crore (~87% of issue) |
| Price Band | ₹461 – ₹485 per share |
| Lot Size | 30 shares | Retail minimum ₹14,550 | Retail maximum 13 lots (390 shares) ₹1,89,150 |
| S-NII / B-NII Minimum | 14 lots (420 shares) ₹2,03,700 | 69 lots (2,070 shares) ₹10,03,950 |
| Quota Split | QIB 50% | NII 15% | Retail 35% |
| Promoters | Green Meadows Investments Ltd., Krishna Chivukula, Krishna Chivukula Jr, Raj Chivukula, Jagadamba Chandrasekhar |
| BRLMs | HDFC Bank, Axis Capital, ICICI Securities, Kotak Mahindra Capital, SBI Capital Markets |
| Registrar | MUFG Intime India Pvt. Ltd. |
| Registered Office | 45(P), KIADB Industrial Area, Hoskote, Bangalore Urban, Karnataka – 562114 |
| Pre-IPO Market Cap | ~₹23,981 crore at upper band |
| Objects of Fresh Issue | ₹400 Cr debt repayment + general corporate purposes (borrowings: ₹1,212.3 Cr as of May 2026) |
| GMP (July 20, 2026) | ₹200–203 (~41% premium; indicative listing ~₹685; range ₹45–205 over recorded period) |
Investors can verify live IPO details and subscription data through the BSE, NSE and registrar platforms before applying. For broader IPO learning, investors can also explore Acumen Capital’s resources at https://acumengroup.in/.
What Does Indo-MIM Actually Make?
Indo-MIM manufactures small, complex metal components using metal injection molding. These components are used in industries where precision, strength, and repeatability matter.
The company’s components may be used in automotive systems, surgical and medical devices, consumer products, aerospace applications, and defence equipment. The uploaded blog notes that Indo-MIM has more than 9,000 product types across multiple end markets.
This matters for investors because Indo-MIM is not a commodity metal-parts company. It operates in a specialised precision engineering niche where customer approvals, tooling, quality standards and process know-how create entry barriers.
Beyond MIM: The Full Technology Stack
| Technology | What It Adds |
| Metal Injection Molding (core) | Small, complex, high-volume precision parts — the flagship capability |
| Investment Casting | Larger metal components where MIM size limits apply |
| Precision Machining | Tight-tolerance finishing and standalone machined parts |
| Ceramic Injection Molding | Wear-resistant, insulating components for medical and industrial uses |
| 3D Metal Printing | Prototyping and low-volume complex geometries — the future-proofing layer |
End markets span automotive (largest), defence including firearms components, a meaningful and sensitive revenue stream medical devices, consumer products, and aerospace. Global reach is real, not aspirational: sales offices in China, Germany and the United States, plus 13 sales representatives across the Czech Republic, France, Italy, Japan, South Korea, Israel, Poland and Turkey.
Financial Performance
| Metric | FY2024 | FY2025 | FY2026 | Trend |
| Total Income | — | ₹3,373.97 Cr | ₹4,320.70 Cr | +28% |
| Revenue (operations) | — | — | ₹4,193 Cr | +26% |
| Profit After Tax | — | ₹423.73 Cr | ₹533.54 Cr | +26% |
| PAT Margin | 9.88% | 12.73% | 12.72% | Stable at higher level |
| EBITDA Margin | — | 28.01% | 25.54% | Softening — watch |
| RoCE | 19.59% | 23.51% | 26.60% | Improving |
| RoNW | — | — | 21.26% | Healthy |
| Avg EPS (3-yr basic) | ₹9.44 | |||
| Dividend | 775% (FY24) | 591% (FY25) | Policy adopted Feb 2025 | Shareholder-friendly |
From the observations, first, the growth is high-quality: PAT margin holding near 12.7% while revenue compounds in the mid-20s, RoCE climbing seven points in two years, and a formal dividend policy rare pre-IPO discipline. Second, the EBITDA margin slide from 28.01% to 25.54% deserves attention. Raw material (metal powder) costs, expansion ramp-up, and mix shifts can all explain it but at 45x earnings, the market is paying for margin stability, not margin erosion. This is the first metric to check in the FY27 results.
Valuation Review: Is Indo-MIM IPO Expensive?
At the upper price band of ₹485, Indo-MIM is valued at around 44.95 times FY26 earnings. This is the main debate in the IPO.
| Metric | Indo-MIM |
| Upper price band | ₹485 |
| FY26 P/E | Around 44.95x |
| FY25 P/E | Around 56.59x |
| PAT margin | Around 12.7% |
| RoNW | 21.26% |
| RoCE | 26.60% |
| Post-IPO P/BV | Around 7.22x |
| Listed Indian peer | No direct domestic listed peer |
The only global listed peer mentioned in the blog is Jiangsu Gian Technology, which trades at a much higher P/E of around 148x. But that comparison needs caution because Jiangsu Gian has weaker margins and return ratios. A high peer multiple does not automatically make Indo-MIM cheap.
The fair investor-side view is this: Indo-MIM is a high-quality business, but the IPO is priced for continued growth. If revenue and profit grow at healthy rates for the next few years, the valuation may be justified. If growth slows or margins decline further, the stock may face valuation pressure.
Indo-MIM IPO GMP
The Indo-MIM IPO GMP was around ₹200 to ₹203 as of July 20, 2026, implying an indicative premium of about 41% over the upper price band. The blog also notes that GMP moved between ₹45 and ₹205 over the recorded period.
For a large ₹3,812 crore issue, listing performance will also depend on institutional demand, final subscription numbers, market conditions, and valuation comfort. Investors should not apply only because GMP looks attractive.
Key Strengths
World’s Largest MIM Components Manufacturer
Indo-MIM has a 6.8% global market share in metal injection molding components. This gives the company leadership in a specialised manufacturing niche.
Strong Customer Base
The company serves more than 1,100 customers across automotive, defence, medical, consumer and aerospace sectors.
Global Manufacturing Footprint
Indo-MIM has 15 manufacturing facilities across India, the US, the UK and Mexico. This gives the company supply-chain diversification and proximity to global customers.
Multi-Technology Capability
The company offers MIM, investment casting, precision machining, ceramic injection molding and 3D metal printing. This makes it a broader precision manufacturing partner.
Debt Reduction from Fresh Issue
Out of the ₹500 crore fresh issue, ₹400 crore is proposed to be used for debt repayment. This may reduce finance costs after listing.
Key Risks
Premium Valuation
At around 44.95x FY26 earnings, the IPO leaves limited room for disappointment. Any slowdown in growth or margin pressure could affect valuation.
Heavy OFS Component
Around 87% of the issue is an offer for Sale. The company receives only the fresh issue portion, while most proceeds go to selling shareholders.
EBITDA Margin Softening
EBITDA margin declined from 28.01% in FY25 to 25.54% in FY26. Investors should track whether this is temporary or the start of margin pressure.
Export and Currency Risk
A large portion of revenue comes from overseas markets. Currency fluctuations, global demand cycles, tariffs, and trade-policy changes can affect earnings.
Raw Material Cost Risk
Fine metal powders and specialised inputs can be costly. Any input price volatility may affect margins.
Defence and Firearms Exposure
The blog mentions revenue exposure to defence and firearm components. This may create regulatory, export-control or ESG-screening risk for some investors.
No Direct Domestic Listed Peer
There is no directly comparable listed Indian peer, making valuation benchmarking difficult.
Acumen Capital’s View
Indo-MIM is a rare and high-quality manufacturing business with global leadership, strong customer relationships, multi-country manufacturing, healthy return ratios and a long runway in precision engineering.
The main issue is valuation. At nearly 45x FY26 earnings, investors are paying upfront for future growth. The IPO may still be attractive for long-term investors if Indo-MIM sustains growth and stabilises margins, but it is not a cheap issue.
GMP indicates positive market sentiment, but GMP should be treated only as a secondary signal. The investment decision should be based on business quality, valuation, margin trend, debt reduction, export demand and personal risk appetite.
Conclusion
The Indo-MIM IPO gives investors exposure to the world’s largest metal injection molding components manufacturer. The company has strong global positioning, diversified end markets, 15 manufacturing facilities, more than 1,100 customers, and healthy FY26 financial performance.
The fresh issue component will help repay debt, which is positive. However, the IPO is largely an OFS, and valuation is demanding at around 44.95x FY26 earnings. The decline in EBITDA margin also deserves monitoring.
Overall, Indo-MIM may appeal to investors who want a specialised global manufacturing business and are willing to hold for the medium to long term. Conservative investors should be cautious about the premium valuation, while listing-gain seekers should avoid depending only on GMP.
FAQs
1. Is Indo-MIM IPO worth applying for?
Indo-MIM IPO may be worth considering for informed medium-to-long-term investors because the company is a global leader in metal injection molding, has strong FY26 growth, healthy return ratios and a diversified customer base. However, the IPO is expensive at around 44.95x FY26 earnings, so investors should not apply only for GMP or listing gains.
2. What is the biggest risk in Indo-MIM IPO?
The biggest risk is premium valuation. At around 44.95x FY26 earnings, the IPO assumes that Indo-MIM will continue delivering strong growth and stable margins. If growth slows or EBITDA margin declines further, the stock may face valuation pressure after listing.
3. Is Indo-MIM IPO a fresh issue or Offer for Sale?
The IPO includes both. It has a ₹500 crore fresh issue and a ₹3,312.11 crore Offer for Sale. Around ₹400 crore from the fresh issue is planned for debt repayment, while the OFS proceeds will go to selling shareholders.
4. Should investors rely on Indo-MIM IPO GMP?
No. GMP is unofficial and can change quickly. Indo-MIM IPO GMP may indicate strong short-term sentiment, but investors should focus more on business quality, valuation, margin trend, debt repayment, export exposure and personal risk appetite.
5. Who should avoid Indo-MIM IPO?
Investors who are uncomfortable with premium valuations, export-linked risks, heavy OFS issues, margin pressure or defence/firearms exposure may prefer to avoid the IPO or wait for post-listing performance before investing.
